Author: Dr. Mukta Goyal & Tanwangini Sahani

Dr. Mukta Goyal¹ & Tanwangini Sahani

DOI Link : https://doi-ds.org/doilink/06.2024-62165657/BIJMRD/Vol -2 / 4/ A2/ Mukta Goyal

Abstract: Synthetic biology and gene editing are cutting-edge technologies poised to transform healthcare and advance Sustainable Development Goal 3 (SDG 3) – “Good Health and Well-being.” Synthetic biology involves designing biological components for novel functions, driving personalized medicine and innovative therapies. Gene editing, especially with CRISPR-Cas9, enables precise DNA modifications, revolutionizing disease treatment and health equity. This research assesses the current state of these technologies, identifies adoption barriers, explores successful applications, and evaluates economic feasibility. Despite their potential, challenges hinder widespread implementation. Through case studies and economic analysis, this study aims to unlock synthetic biology and gene editing’s full potential in achieving SDG 3, ensuring healthier lives worldwide.

Key words: Synthetic biology, Gene editing, Personalized medicine, CRISPR-Cas9, DNA modifications, Innovation

Page no : 57-65